Polycystic ovary syndrome (PCOS) occupies a leading position among all the main causes of hyperandrogenism and, as a consequence, amenorrhea, menstrual cycle disorders in women of fertile age. There is a tendency to use different approaches in the treatment and monitoring of this condition, which can lead to the realization of potentially poor prognoses. According to a survey of 357 members of the European Society of Endocrinologists, despite modern international recommendations on the use of combined oral contraceptives (COCs) as the first-choice drugs for the correction of menstrual disorders and the treatment of hirsutism, metformin was preferred more often.
COCs in the form of monophasic, multiphase drugs, as well as monocomponent drugs, allow for an individualized approach in the treatment of women with PCOS, taking into account the already existing concomitant pathology, possible risks of both the syndrome itself and the effects of the use of these drugs. To this date, there is no convincing data confirming the advantage of one COC drug over another. All women with PCOS should be motivated to modify their lifestyle and timely follow-up.Ключевые слова:
Автор(ы): O. D. Lazovtseva, T. V. Mokhort